Exelixis/$EXEL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Ticker

$EXEL
Primary listing

Industry

Biotechnology

Employees

1,147

ISIN

US30161Q1040

Exelixis Metrics

BasicAdvanced
$12B
19.55
$2.20
0.25
-

What the Analysts think about Exelixis

Analyst ratings (Buy, Hold, Sell) for Exelixis stock.

Bulls say / Bears say

Exelixis reported strong financial results for Q4 2024, with total revenues reaching $567 million, driven by a 20% year-over-year increase in U.S. cabozantinib net product revenues to $515 million. (thetelegraph.com)
The company has a robust pipeline, including zanzalintinib, which analysts estimate could reach $5 billion in net U.S. sales by 2033, targeting multiple indications such as renal cell carcinoma and colorectal cancer. (finviz.com)
Exelixis authorized a $450 million share repurchase in 2024, following a $550 million repurchase in 2023, indicating strong financial health and commitment to returning value to shareholders. (markets.businessinsider.com)
Despite FDA approval of Cabometyx for advanced neuroendocrine tumors, shares fell 2.3% as analysts noted the approval was already priced into the stock. (tradingview.com)
Barclays analyst Peter Lawson maintained a Hold rating on Exelixis with a price target of $25, suggesting limited upside potential. (markets.businessinsider.com)
The company announced a corporate restructuring resulting in a 13% workforce reduction, which may indicate internal challenges or a need to streamline operations. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Exelixis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Exelixis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EXEL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs